Cognition Therapeutics, Inc. (CGTX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CGTX SEC filings page.
This page shows Cognition Therapeutics, Inc. (CGTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cognition remains a research-funded development business: FY2025 losses narrowed through lower spending, while financing enlarged its balance sheet.
The FY2025 improvement was a spending story, not demonstrated operating leverage: operating loss narrowed to$47.8M while R&D fell to$37.2M . With no reported revenue, the smaller loss cannot yet be attributed to scale; research remains the dominant expense, so the change reflects cost reduction more than commercial growth.
A financing inflow of
Operating cash flow of
Financial Health Signals
Cognition Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cognition Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Cognition Therapeutics, Inc. reported a net loss of $23.5M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Cognition Therapeutics, Inc. reported an operating loss of $47.8M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cognition Therapeutics, Inc. reported -$3.9M in net income in Q2 2026. This represents an increase of 41.6% from the same quarter a year earlier. Against the prior quarter it is up 14.0%.
Cognition Therapeutics, Inc. earned -$0.04 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 20.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Cognition Therapeutics, Inc. held $34.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Cognition Therapeutics, Inc.'s ROE was -11.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 83.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.4 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Cognition Therapeutics, Inc. invested $5.1M in research and development in Q2 2026. This represents a decrease of 55.6% from the same quarter a year earlier. Against the prior quarter it is down 16.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
CGTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $5.1M-55.6% | $6.1M-43.3% | N/A | $3.8M-66.9% | $11.5M-0.8% | $10.8M+2.2% | N/A | $11.4M-2.4% |
| SG&A Expenses | $2.6M+5.8% | $2.7M-9.8% | N/A | $2.6M-15.3% | $2.5M-19.5% | $3.0M-15.8% | N/A | $3.1M-0.2% |
| Operating Income | -$7.7M+44.6% | -$8.8M+36.0% | N/A | -$6.4M+55.9% | -$14.0M+4.8% | -$13.8M+2.3% | N/A | -$14.5M+1.9% |
| EBITDA | N/A | N/A | N/A | -$6.4M+55.9% | N/A | N/A | N/A | -$14.4M+1.9% |
| Interest Expense | $3K0.0% | $5K0.0% | N/A | N/A | $3K-57.1% | $5K-50.0% | N/A | $3K+50.0% |
| Net Income | -$3.9M+41.6% | -$4.6M+46.1% | N/A | -$4.9M+50.4% | -$6.7M+4.4% | -$8.5M+7.3% | N/A | -$9.9M-47.2% |
| EPS (Basic) | -$0.04+63.6% | -$0.05+64.3% | -$0.02+88.2% | -$0.06+76.0% | -$0.11+38.9% | -$0.14+48.1% | -$0.17+37.0% | -$0.25-13.6% |
| EPS (Diluted) | -$0.04 | -$0.05 | -$0.02+88.2% | -$0.06 | -$0.11 | -$0.14 | -$0.17+37.0% | -$0.25-13.6% |
| Diluted Shares (Avg) | 91M | 89M | N/A | 78M | 64M | 62M | N/A | 40M+33.1% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
CGTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $38.9M+98.2% | $36.1M+53.8% | $48.4M+60.1% | $43.4M+57.3% | $19.6M-42.9% | $23.5M-39.5% | $30.2M-14.0% | $27.6M-28.9% |
| Current Assets | $38.3M+101.1% | $35.8M+56.6% | $48.0M+62.4% | $42.9M+59.8% | $19.0M-43.2% | $22.9M-39.8% | $29.6M-13.6% | $26.8M-25.6% |
| Cash & Equivalents | $34.0M+216.6% | $31.1M+89.5% | $36.8M+47.2% | $39.3M+78.7% | $10.7M-62.3% | $16.4M-52.6% | $25.0M-16.4% | $22.0M-33.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.9M-53.4% | $6.2M-44.5% | $14.1M+22.9% | $6.9M-47.6% | $12.6M+10.9% | $11.2M+12.4% | $11.5M+7.4% | $13.1M+33.0% |
| Current Liabilities | $5.5M-55.9% | $6.1M-44.7% | $13.9M+25.0% | $6.7M-47.6% | $12.4M+13.2% | $10.9M+15.2% | $11.1M+9.6% | $12.7M+54.4% |
| Non-Current Liabilities | $422K+84.3% | $176K-37.1% | $195K-43.0% | $212K-45.9% | $229K-48.0% | $280K-42.6% | $342K-34.2% | $392K-75.8% |
| Total Equity | $33.0M+369.8% | $29.9M+143.8% | $34.3M+82.8% | $36.5M+152.2% | $7.0M-69.5% | $12.3M-57.5% | $18.8M-23.4% | $14.5M-49.9% |
| Retained Earnings | -$207.1M-8.8% | -$203.2M-10.7% | -$198.6M-13.4% | -$195.3M-16.7% | -$190.4M-21.0% | -$183.6M-22.1% | -$175.2M-24.1% | -$167.3M-25.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CGTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M+45.7% | -$5.5M+43.9% | -$3.4M+59.0% | -$5.7M+17.5% | -$5.6M+6.2% | -$9.9M-36.3% | -$8.4M-53.6% | -$6.9M-64.6% |
| Depreciation & Amortization | N/A | N/A | $14K-48.1% | $15K-44.4% | N/A | N/A | $27K0.0% | $27K+8.0% |
| Stock-Based Compensation | $319K-48.6% | $330K-43.7% | N/A | $522K-41.7% | $621K-45.9% | $586K-50.0% | N/A | $896K-16.3% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $1K-96.7% | $0-100.0% |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$8.4M-52.8% | -$6.9M-62.4% |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$1K+96.7% | $0+100.0% |
| Financing Cash Flow | $6.6M+779.0% | -$233K-118.0% | $605K-94.7% | $33.9M+10209.1% | $752K+644.9% | $1.3M-89.2% | $11.4M+366.6% | $329K+11066.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CGTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -11.9%+83.9pp | -15.3%+53.8pp | N/A | -13.5%+55.1pp | -95.8%-65.2pp | -69.1%-37.4pp | N/A | -68.6%-45.3pp |
| Return on Assets | -10.1%+24.2pp | -12.7%+23.4pp | N/A | -11.4%+24.7pp | -34.3%-13.8pp | -36.1%-12.5pp | N/A | -36.0%-18.6pp |
| Current Ratio | 7.03+5.5x | 5.92+3.8x | 3.45+0.8x | 6.44+4.3x | 1.54-1.5x | 2.09-1.9x | 2.65-0.7x | 2.11-2.3x |
| Debt-to-Equity | 0.18-1.6x | 0.21-0.7x | 0.41-0.2x | 0.19-0.7x | 1.79+1.3x | 0.92+0.6x | 0.61+0.2x | 0.90+0.6x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. CGTX | FY2025 | N/A | -$23.5M | N/A | $83.4M | — |
| Entrada Therapeutics, Inc. TRDA | FY2025 | $25.4M | -$143.8M | N/A | $220.8M | 41/100 |
| Voyager Therapeutics, Inc. VYGR | FY2025 | $40.4M | -$119.7M | N/A | $151.0M | 48/100 |
| Tiziana Life Sciences Ltd. TLSA | FY2025 | N/A | -$18.4M | N/A | $151.4M | — |
| Tenaya Therapeutics, Inc. TNYA | FY2025 | N/A | -$90.6M | N/A | $130.1M | — |
Where Cognition Therapeutics, Inc. Ranks
Frequently Asked Questions
Is Cognition Therapeutics, Inc. profitable?
No, Cognition Therapeutics, Inc. (CGTX) reported a net income of -$23.5M in fiscal year 2025.
What is Cognition Therapeutics, Inc.'s EBITDA?
Cognition Therapeutics, Inc. (CGTX) had EBITDA of -$47.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cognition Therapeutics, Inc.'s return on equity (ROE)?
Cognition Therapeutics, Inc. (CGTX) has a return on equity of -68.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cognition Therapeutics, Inc.'s operating cash flow?
Cognition Therapeutics, Inc. (CGTX) recorded an outflow of $24.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cognition Therapeutics, Inc.'s total assets?
Cognition Therapeutics, Inc. (CGTX) had $48.4M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Cognition Therapeutics, Inc. spend on research and development?
Cognition Therapeutics, Inc. (CGTX) invested $37.2M in research and development during fiscal year 2025.
What is Cognition Therapeutics, Inc.'s current ratio?
Cognition Therapeutics, Inc. (CGTX) had a current ratio of 3.45 as of fiscal year 2025, which is generally considered healthy.
What is Cognition Therapeutics, Inc.'s debt-to-equity ratio?
Cognition Therapeutics, Inc. (CGTX) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cognition Therapeutics, Inc.'s return on assets (ROA)?
Cognition Therapeutics, Inc. (CGTX) had a return on assets of -48.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cognition Therapeutics, Inc.'s P/E ratio?
Cognition Therapeutics, Inc. (CGTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $83.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Cognition Therapeutics, Inc.'s price-to-sales ratio?
Cognition Therapeutics, Inc. (CGTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $83.4M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Cognition Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Cognition Therapeutics, Inc. (CGTX) held $36.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $24.6M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Cognition Therapeutics, Inc.'s Piotroski F-Score?
Cognition Therapeutics, Inc. (CGTX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cognition Therapeutics, Inc.'s earnings high quality?
Cognition Therapeutics, Inc. (CGTX) reported a net loss of $23.5M while operations used $24.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cognition Therapeutics, Inc. cover its interest payments?
Cognition Therapeutics, Inc. (CGTX) reported an operating loss of $47.8M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.